Offers Offers September of 2024 Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective € 2050.00 € 1640.00 March of 2024 2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics € 130.00 € 104.00 August of 2023 Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective € 2150.00 € 1720.00 February of 2023 Antibody Target, Technology & Pipeline Database: 1-Year Subscription € 1600.00 € 1280.00 July of 2022 Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis € 2550.00 € 1800.00 July and October of 2021 2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount € 4400.00 € 2200.00 May of 2020 Report Package: “Drug the Undruggable” Technologies € 8250.00 € 4125.00 June of 2019 Report Package: Bispecific Antibodies € 3150.00 € 2500.00 May of 2018 Report Package: TCR-Based Antibody and T-Cell Immunotherapy € 4450.00 € 2670.00 January of 2018 Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends € 2300.00 € 2000.00
